Choate represented Perceptive Xontogeny Venture Fund in the transaction. AsclepiX Therapeutics, Inc. has closed a $35 million Series A financing led by Perceptive Xontogeny Venture Fund…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now